# Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

> **NCT01828762** · NA · COMPLETED · sponsor: **Shanghai AbelZeta Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Primary Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** DC-TC+GM-CSF

## Key facts

- **NCT ID:** NCT01828762
- **Lead sponsor:** Shanghai AbelZeta Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-12
- **Final completion:** —
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2013-12-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01828762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01828762, "Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01828762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*